Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Barclays PLC

Barclays PLC grew its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 16.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 99,148 shares of the company's stock after purchasing an additional 13,753 shares during the period. Barclays PLC owned approximately 0.16% of Vera Therapeutics worth $4,192,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in VERA. Huntington National Bank purchased a new stake in Vera Therapeutics in the fourth quarter valued at about $26,000. AlphaQuest LLC purchased a new position in shares of Vera Therapeutics in the fourth quarter worth $34,000. KBC Group NV lifted its stake in shares of Vera Therapeutics by 127.2% during the fourth quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after buying an additional 1,387 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after buying an additional 639 shares during the period. Finally, Moors & Cabot Inc. purchased a new stake in shares of Vera Therapeutics during the fourth quarter valued at $220,000. Institutional investors and hedge funds own 99.21% of the company's stock.

Vera Therapeutics Price Performance

VERA stock traded down $0.63 during midday trading on Wednesday, reaching $23.37. The stock had a trading volume of 767,031 shares, compared to its average volume of 747,618. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $51.61. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The company's fifty day simple moving average is $25.03 and its 200 day simple moving average is $35.64. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -8.95 and a beta of 1.28.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.11. As a group, sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on VERA. Guggenheim boosted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. Wolfe Research initiated coverage on Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective for the company. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 target price on the stock. Finally, JPMorgan Chase & Co. decreased their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Vera Therapeutics presently has an average rating of "Buy" and a consensus price target of $64.67.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.